Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy
Abstract
:1. Introduction
2. Combretastatin A-4 Analogues
3. Indole Analogues
4. Thiophene and Quinolone Analogs
5. Chalcone Analogs
6. Trimethoxy Phenyl Analogs
7. Approved and Promising Antimitotic Agents
8. Conclusions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Boyle, P.; Levin, B. World Cancer Report 2008; WHO report; The International Agency for Research on Cancer: Lyon, France, 2008; pp. 12–510. [Google Scholar]
- Heptinstall, A.B.; Adiyasa, I.; Cano, C.; Hardcastle, I.R. Recent advances in CDK inhibitors for cancer therapy. Future Med. Chem. 2018, 10, 1369–1388. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baytas, S.N.; Inceler, N.; Yılmaz, A. Synthesis, cytotoxicity, and molecular properties prediction of novel 1,3-diarylpyrazole derivatives. Med. Chem. Res. 2013, 22, 4893–4908. [Google Scholar] [CrossRef]
- Hawash, M.; Jaradat, N.; Eid, A.M.; Abubaker, A.; Mufleh, O.; Al-Hroub, Q.; Sobuh, S. Synthesis of novel isoxazole–carboxamide derivatives as promising agents for melanoma and targeted nano-emulgel conjugate for improved cellular permeability. BMC Chem. 2022, 16, 47. [Google Scholar] [CrossRef] [PubMed]
- Patrick, G.L. An Introduction to Medicinal Chemistry; Oxford University Press: Oxford, UK, 2013. [Google Scholar]
- Hawash, M. Highlights on Specific Biological Targets; Cyclin-Dependent Kinases, Epidermal Growth Factor Receptors, Ras Protein, and Cancer Stem Cells in Anticancer Drug Development. Drug Res. 2019, 69, 471–478. [Google Scholar] [CrossRef]
- Singh, H.; Kumar, M.; Nepali, K.; Gupta, M.K.; Saxena, A.K.; Sharma, S.; Bedi, P.M.S. Triazole tethered C5-curcuminoid-coumarin based molecular hybrids as novel antitubulin agents: Design, synthesis, biological investigation and docking studies. Eur. J. Med. Chem. 2016, 116, 102–115. [Google Scholar] [CrossRef]
- Bhattacharyya, B.; Panda, D.; Gupta, S.; Banerjee, M. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med. Res. Rev. 2008, 28, 155–183. [Google Scholar] [CrossRef]
- Ducki, S. Antimitotic Chalcones and Related Compounds as Inhibitors of Tubulin Assembly. Anti-Cancer Agents Med. Chem. 2009, 9, 336. [Google Scholar] [CrossRef]
- Flynn, B.L.; Hamel, E.; Jung, M.K. One-Pot Synthesis of Benzo[b]furan and Indole Inhibitors of Tubulin Polymerization. J. Med. Chem. 2002, 45, 2670–2673. [Google Scholar] [CrossRef]
- Hamel, E. Evaluation of Antimitotic Agents by Quantitative Comparisons of Their Effects on the Polymerization of Purified Tubulin. Cell Biochem. Biophys. 2003, 38, 1–21. [Google Scholar] [CrossRef]
- Arnst, K.E.; Wang, Y.; Hwang, D.-J.; Xue, Y.; Costello, T.; Hamilton, D.; Chen, Q.; Yang, J.; Park, F.; Dalton, J.T. A potent, metabolically stable tubulin inhibitor targets the colchicine binding site and overcomes taxane resistance. Cancer Res. 2018, 78, 265–277. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brossi, A.; Yeh, H.J.; Chrzanowska, M.; Wolff, J.; Hamel, E.; Lin, C.M.; Quin, F.; Suffness, M.; Silverton, J. Colchicine and its analogues: Recent findings. Med. Res. Rev. 1988, 8, 77–94. [Google Scholar] [CrossRef] [PubMed]
- Ben-Chetrit, E.; Levy, M. Colchicine: 1998 update. In Seminars in Arthritis and Rheumatism; Elsevier: Amsterdam, The Netherlands, 1998; pp. 48–59. [Google Scholar]
- Lu, Y.; Chen, J.; Wang, J.; Li, C.-M.; Ahn, S.; Barrett, C.M.; Dalton, J.T.; Li, W.; Miller, D.D. Design, synthesis, and biological evaluation of stable colchicine binding site tubulin inhibitors as potential anticancer agents. J. Med. Chem. 2014, 57, 7355–7366. [Google Scholar] [CrossRef] [Green Version]
- Abma, E.; Daminet, S.; Smets, P.; Ni, Y.; De Rooster, H. Combretastatin A4-phosphate and its potential in veterinary oncology: A review. Vet. Comp. Oncol. 2017, 15, 184–193. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hawash, M.; Jaradat, N.; Abualhasan, M.; Amer, J.; Levent, S.; Issa, S.; Ibrahim, S.; Ayaseh, A.; Shtayeh, T.; Mousa, A. Synthesis, chemo-informatics, and anticancer evaluation of fluorophenyl-isoxazole derivatives. Open Chem. 2021, 19, 855–863. [Google Scholar] [CrossRef]
- Nepali, K.; Ojha, R.; Sharma, S.; MS Bedi, P.; L Dhar, K. Tubulin inhibitors: A patent survey. Recent Pat. Anti-Cancer Drug Discov. 2014, 9, 176–220. [Google Scholar] [CrossRef]
- Ley, C.D.; Horsman, M.R.; Paul, E.G.; Kristjansen, P.E.G. Early Effects of Combretastatin-A4 Disodium Phosphate on Tumor Perfusion and Interstitial Fluid Pressure. Neoplasia 2007, 9, 108–112. [Google Scholar] [CrossRef] [Green Version]
- Gutiérrez, S.T.; Oltra, S.D.; Falomir, E.; Murga, J.; Carda, M.; Marco, J.A. Synthesis of combretastatin A-4 O-alkyl derivatives and evaluation of their cytotoxic, antiangiogenic and antitelomerase activity. Bioorganic Med. Chem. J. 2013, 21, 7267–7274. [Google Scholar] [CrossRef] [Green Version]
- Baytas, S.N.; Inceler, N.; Yılmaz, A.; Olgac, A.; Menevse, S.; Banoglu, E.; Hamel, E.; Bortolozzi, R.; Viola, G. Synthesis, biological evaluation and molecular docking studies of trans-indole-3-acrylamide derivatives, a new class of tubulin polymerization inhibitors. Bioorganic Med. Chem. 2014, 22, 3096–3104. [Google Scholar] [CrossRef] [Green Version]
- Gao, M.; Zhang, D.; Jin, Q.; Jiang, C.; Wang, C.; Li, J.; Peng, F.; Huang, D.; Zhang, J.; Song, S. Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model. Oncotarget Impact J. 2016, 7, 58133–58141. [Google Scholar] [CrossRef]
- Nathan, P.; Zweifel, M.; Padhani, A.R.; Koh, D.M.; Ng, M.; Collins, D.J.; Harris, A.; Carden, C.; Smythe, J.; Fisher, N.; et al. Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer. Clin. Cancer Res. 2012, 18, 3428–3439. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Simoni, D.; Romagnoli, R.; Baruchello, R.; Rondanin, R.; Rizzi, M.; Pavani, M.G.; Alloatti, D.; Giannini, G.; Marcellini, M.; Riccioni, T. Novel combretastatin analogues endowed with antitumor activity. J. Med. Chem. 2006, 49, 3143–3152. [Google Scholar] [CrossRef] [PubMed]
- Stevenson, J.P.; Rosen, M.; Sun, W.; Gallagher, M.; Haller, D.G.; Vaughn, D.; Giantonio, B.; Zimmer, R.; Petros, W.P.; Stratford, M. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol. 2003, 21, 4428–4438. [Google Scholar] [CrossRef] [PubMed]
- Hawash, M.; Jaradat, N.; Abualhasan, M.; Qneibi, M.; Rifai, H.; Saqfelhait, T.; Shqirat, Y.; Nazal, A.; Omarya, S.; Ibrahim, T.; et al. Evaluation of cytotoxic, COX inhibitory, and antimicrobial activities of novel isoxazole-carboxamide derivatives. Lett. Drug Des. Discov. 2022, 19. [Google Scholar] [CrossRef]
- Tron, G.C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A.A. Medicinal chemistry of combretastatin A4: Present and future directions. J. Med. Chem. 2006, 49, 3033–3044. [Google Scholar] [CrossRef]
- Aprile, S.; Del Grosso, E.; Tron, G.C.; Grosa, G. In vitro metabolism study of combretastatin A-4 in rat and human liver microsomes. Drug Metab. Dispos. 2007, 35, 2252–2261. [Google Scholar] [CrossRef] [Green Version]
- Eid, A.M.; Hawash, M.; Amer, J.; Jarrar, A.; Qadri, S.; Alnimer, I.; Sharaf, A.; Zalmoot, R.; Hammoudie, O.; Hameedi, S. Synthesis and Biological Evaluation of Novel Isoxazole-Amide Analogues as Anticancer and Antioxidant Agents. BioMed Res. Int. 2021, 2021, 6633297. [Google Scholar] [CrossRef]
- Li, D.-D.; Qin, Y.-J.; Zhang, X.; Yin, Y.; Zhu, H.-L.; Zhao, L.-G. Combined Molecular Docking, 3D-QSAR, and Pharmacophore Model: Design of Novel Tubulin Polymerization Inhibitors by Binding to Colchicine-binding Site. Chem. Biol. Drug Des. 2015, 86, 731–745. [Google Scholar] [CrossRef]
- Reddy, N.R.; Gouse, S.; Selvaraju, S.; Baskaran, S. Domino Semipinacol/Iterative Aldol/Iso-Nazarov Cyclization to Triaryl-cyclopentenone: Enantioselective Synthesis of Combretastatin A-4 Analogues. Org. Lett. 2022, 24, 4240–4245. [Google Scholar] [CrossRef]
- Reddy, T.S.; Rai, S.; Koppula, S.K. Synthesis of indole-tetrazole coupled aromatic amides; In vitro anticancer activity, in vitro tubulin polymerization inhibition assay and in silico studies. J. Mol. Struct. 2022, 1267, 133556. [Google Scholar] [CrossRef]
- Ohsumi, K.; Hatanaka, T.; Fujita, K.; Nakagawa, R.; Fukuda, Y.; Nihei, Y.; Suga, Y.; Morinaga, Y.; Akiyama, Y.; Tsuji, T. Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues. Bioorganic Med. Chem. Lett. 1998, 8, 3153–3158. [Google Scholar] [CrossRef]
- Yang, T.; Wang, Y.; Li, Z.; Dai, W.; Yin, J.; Liang, L.; Ying, X.; Zhou, S.; Wang, J.; Zhang, X.; et al. Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. Nanomedicine 2012, 8, 81–92. [Google Scholar] [CrossRef] [PubMed]
- Huang, X.; Chen, Y.; Zhong, W.; Liu, Z.; Zhang, H.; Zhang, B.; Wang, H. Novel combretastatin A-4 derivative containing aminophosphonates as dual inhibitors of tubulin and matrix metalloproteinases for lung cancer treatment. Eur. J. Med. Chem. 2022, 244, 114817. [Google Scholar] [CrossRef] [PubMed]
- Mustafa, M.; A Mostafa, Y.; E Abd Elbaky, A.; Mohamed, M.; Abdelhamid, D.; MN Abdelhafez, E.; Aly, O.M. Combretastatin A-4 analogs: Past, present, and future directions. Octahedron Drug Res. 2022, 1, 55–64. [Google Scholar] [CrossRef]
- Nakamura, M.; Kajita, D.; Matsumoto, Y.; Hashimoto, Y. Design and synthesis of silicon-containing tubulin polymerization inhibitors: Replacement of the ethylene moiety of combretastatin A-4 with a silicon linker. Bioorganic Med. Chem. J. 2013, 21, 7381–7391. [Google Scholar] [CrossRef] [PubMed]
- dos Santos, E.d.A.; Hamel, E.; Bai, R.; Burnett, J.C.; Tozatti, C.S.S.; Bogo, D.; Perdomo, R.T.; Antunes, A.M.; Marques, M.M.; de FC Matos, M. Synthesis and evaluation of diaryl sulfides and diaryl selenide compounds for antitubulin and cytotoxic activity. Bioorganic Med. Chem. Lett. 2013, 23, 4669–4673. [Google Scholar] [CrossRef] [Green Version]
- Soussi, M.A.; Provot, O.; Bernadat, G.; Bignon, J.; Wdzieczak-Bakala, J.; Desravines, D.; Dubois, J.; Brion, J.-D.; Messaoudi, S.; Alami, M. Discovery of azaisoerianin derivatives as potential antitumors agents. Eur. J. Med. Chem. 2014, 78, 178–189. [Google Scholar] [CrossRef]
- Herdman, C.A.; Strecker, T.E.; Tanpure, R.P.; Chen, Z.; Winters, A.; Gerberich, J.; Liu, L.; Hamel, E.; Mason, R.P.; Chaplin, D.J. Synthesis and biological evaluation of benzocyclooctene-based and indene-based anticancer agents that function as inhibitors of tubulin polymerization. MedChemComm 2016, 7, 2418–2427. [Google Scholar] [CrossRef] [Green Version]
- Simoni, D.; Grisolia, G.; Giannini, G.; Roberti, M.; Rondanin, R.; Piccagli, L.; Baruchello, R.; Rossi, M.; Romagnoli, R.; Invidiata, F.P. Heterocyclic and phenyl double-bond-locked combretastatin analogues possessing potent apoptosis-inducing activity in HL60 and in MDR cell lines. J. Med. Chem. 2005, 48, 723–736. [Google Scholar] [CrossRef]
- Sharma, S.; Kumar Gupta, M.; Kumar Saxena, A.; Singh Bedi, P.M. Thiazolidinone constraint combretastatin analogs as novel antitubulin agents: Design, synthesis, biological evaluation and docking studies. Anti-Cancer Agents Med. Chem. (Former. Curr. Med. Chem.-Anti-Cancer Agents) 2017, 17, 230–240. [Google Scholar] [CrossRef]
- Guan, Q.; Zuo, D.; Jiang, N.; Qi, H.; Zhai, Y.; Bai, Z.; Feng, D.; Yang, L.; Jiang, M.; Bao, K. Microwave-assisted synthesis and biological evaluation of 3,4-diaryl maleic anhydride/N-substituted maleimide derivatives as combretastatin A-4 analogues. Bioorganic Med. Chem. Lett. 2015, 25, 631–634. [Google Scholar] [CrossRef] [PubMed]
- Barreca, M.; Spanò, V.; Raimondi, M.V.; Tarantelli, C.; Spriano, F.; Bertoni, F.; Barraja, P.; Montalbano, A. Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity. Eur. J. Med. Chem. Rep. 2021, 1, 100004. [Google Scholar] [CrossRef]
- Singh, H.; Singh, J.V.; Gupta, M.K.; Saxena, A.K.; Sharma, S.; Nepali, K.; Bedi, P.M.S. Triazole tethered isatin-coumarin based molecular hybrids as novel antitubulin agents: Design, synthesis, biological investigation and docking studies. Bioorganic Med. Chem. Lett. 2017, 27, 3974–3979. [Google Scholar] [CrossRef]
- Blanch, N.M.; Chabot, G.G.; Quentin, L.; Scherman, D.; Bourg, S.; Dauzonne, D. In vitro and in vivo biological evaluation of new 4,5-disubstituted 1,2,3-triazoles as cis-constrained analogs of combretastatin A4. Eur. J. Med. Chem. 2012, 54, 22–32. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, L.; Woods, K.W.; Li, Q.; Barr, K.J.; McCroskey, R.W.; Hannick, S.M.; Gherke, L.; Credo, R.B.; Hui, Y.-H.; Marsh, K. Potent, orally active heterocycle-based combretastatin A-4 analogues: Synthesis, structure− activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J. Med. Chem. 2002, 45, 1697–1711. [Google Scholar] [CrossRef] [PubMed]
- Romagnoli, R.; Baraldi, P.G.; Salvador, M.K.; Camacho, M.E.; Preti, D.; Tabrizi, M.A.; Bassetto, M.; Brancale, A.; Hamel, E.; Bortolozzi, R. Synthesis and biological evaluation of 2-substituted-4-(3′,4′,5′-trimethoxyphenyl)-5-aryl thiazoles as anticancer agents. Bioorganic Med. Chem. 2012, 20, 7083–7094. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- O’Boyle, N.M.; Pollock, J.K.; Carr, M.; Knox, A.J.; Nathwani, S.M.; Wang, S.; Caboni, L.; Zisterer, D.M.; Meegan, M.J. β-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand. J. Med. Chem. 2014, 57, 9370–9382. [Google Scholar] [CrossRef] [PubMed]
- Greene, T.F.; Wang, S.; Greene, L.M.; Nathwani, S.M.; Pollock, J.K.; Malebari, A.M.; McCabe, T.; Twamley, B.; O’Boyle, N.M.; Zisterer, D.M. Synthesis and biochemical evaluation of 3-phenoxy-1,4-diarylazetidin-2-ones as tubulin-targeting antitumor agents. J. Med. Chem. 2016, 59, 90–113. [Google Scholar] [CrossRef]
- Malebari, A.M.; Duffy Morales, G.; Twamley, B.; Fayne, D.; Khan, M.F.; McLoughlin, E.C.; O’Boyle, N.M.; Zisterer, D.M.; Meegan, M.J. Synthesis, Characterisation and Mechanism of Action of Anticancer 3-Fluoroazetidin-2-ones. Pharmaceuticals 2022, 15, 1044. [Google Scholar] [CrossRef]
- Peng, Y.; Shi, Z.; Liang, Y.; Ding, K.; Wang, Y. Targeting the tumor microenvironment by an enzyme-responsive prodrug of tubulin destabilizer for triple-negative breast cancer therapy with high safety. Eur. J. Med. Chem. 2022, 236, 114344. [Google Scholar] [CrossRef]
- O’Boyle, N.M.; Carr, M.; Greene, L.M.; Bergin, O.; Nathwani, S.M.; McCabe, T.; Lloyd, D.G.; Zisterer, D.M.; Meegan, M.J. Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents. J. Med. Chem. 2010, 53, 8569–8584. [Google Scholar] [CrossRef] [PubMed]
- Zhou, P.; Liu, Y.; Zhou, L.; Zhu, K.; Feng, K.; Zhang, H.; Liang, Y.; Jiang, H.; Luo, C.; Liu, M. Potent antitumor activities and structure basis of the chiral β-lactam bridged analogue of combretastatin A-4 binding to tubulin. J. Med. Chem. 2016, 59, 10329–10334. [Google Scholar] [CrossRef] [PubMed]
- Yan, J.; Pang, Y.; Sheng, J.; Wang, Y.; Chen, J.; Hu, J.; Huang, L.; Li, X. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells. Biochem. Pharmacol. 2015, 97, 51–61. [Google Scholar] [CrossRef]
- Rasolofonjatovo, E.; Provot, O.; Hamze, A.; Rodrigo, J.; Bignon, J.; Wdzieczak-Bakala, J.; Lenoir, C.; Desravines, D.; Dubois, J.; Brion, J.-D. Design, synthesis and anticancer properties of 5-arylbenzoxepins as conformationally restricted isocombretastatin A-4 analogs. Eur. J. Med. Chem. 2013, 62, 28–39. [Google Scholar] [CrossRef] [PubMed]
- LeBlanc, R.; Dickson, J.; Brown, T.; Stewart, M.; Pati, H.N.; VanDerveer, D.; Arman, H.; Harris, J.; Pennington, W.; Holt, H.L., Jr. Synthesis and cytotoxicity of epoxide and pyrazole analogs of the combretastatins. Bioorganic Med. Chem. 2005, 13, 6025–6034. [Google Scholar] [CrossRef]
- Zaninetti, R.; Cortese, S.V.; Aprile, S.; Massarotti, A.; Canonico, P.L.; Sorba, G.; Grosa, G.; Genazzani, A.A.; Pirali, T. A Concise Synthesis of Pyrazole Analogues of Combretastatin A1 as Potent Anti-Tubulin Agents. ChemMedChem 2013, 8, 633–643. [Google Scholar] [CrossRef]
- Hawash, M.; Jaradat, N.; Bawwab, N.; Salem, K.; Arafat, H.; Hajyousef, Y.; Shtayeh, T.; Sobuh, S. Design, synthesis, and biological evaluation of phenyl-isoxazole-carboxamide derivatives as anticancer agents. Heterocycl. Commun. 2021, 27, 133–141. [Google Scholar] [CrossRef]
- Leslie, B.J.; Holaday, C.R.; Nguyen, T.; Hergenrother, P.J. Phenylcinnamides as novel antimitotic agents. J. Med. Chem. 2010, 53, 3964–3972. [Google Scholar] [CrossRef]
- Kamal, A.; Shaik, A.B.; Rao, B.B.; Khan, I.; Kumar, G.B.; Jain, N. Design and synthesis of pyrazole/isoxazole linked arylcinnamides as tubulin polymerization inhibitors and potential antiproliferative agents. Org. Biomol. Chem. 2015, 13, 10162–10178. [Google Scholar] [CrossRef]
- Ma, J.; Bao, G.; Wang, L.; Li, W.; Xu, B.; Du, B.; Lv, J.; Zhai, X.; Gong, P. Design, synthesis, biological evaluation and preliminary mechanism study of novel benzothiazole derivatives bearing indole-based moiety as potent antitumor agents. Eur. J. Med. Chem. 2015, 96, 173–186. [Google Scholar] [CrossRef]
- Liou, J.-P.; Wu, Z.-Y.; Kuo, C.-C.; Chang, C.-Y.; Lu, P.-Y.; Chen, C.-M.; Hsieh, H.-P.; Chang, J.-Y. Discovery of 4-amino and 4-hydroxy-1-aroylindoles as potent tubulin polymerization inhibitors. J. Med. Chem. 2008, 51, 4351–4355. [Google Scholar] [CrossRef] [PubMed]
- Abdellatif, K.R.; Lamie, P.F.; Omar, H.A. 3-methyl-2-phenyl-1-substituted-indole derivatives as indomethacin analogs: Design, synthesis and biological evaluation as potential anti-inflammatory and analgesic agents. J. Enzym. Inhib. Med. Chem. 2016, 31, 318–324. [Google Scholar] [CrossRef]
- Sharma, V.; Kumar, P.; Pathaka, D. Biological Importance of the Indole Nucleus in Recent Years: A Comprehensive Review. J. Heterocycl. Chem. 2010, 47, 491–502. [Google Scholar] [CrossRef]
- Zhang, M.Z.; Chen, Q.; Yang, G.F. A review on recent developments of indole-containing antiviral agents. Eur. J. Med. Chem. 2015, 89, 421–441. [Google Scholar] [CrossRef] [PubMed]
- Cihan-Ustundag, G.; Gursoy, E.; Naesens, L.; Ulusoy-Guzeldemirci, N.; Capan, G. Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones. Bioorganic Med. Chem. J. 2016, 24, 240–246. [Google Scholar] [CrossRef]
- De Martino, G.; La Regina, G.; Coluccia, A.; Edler, M.C.; Barbera, M.C.; Brancale, A.; Wilcox, E.; Hamel, E.; Artico, M.; Silvestri, R. Arylthioindoles, Potent Inhibitors of Tubulin Polymerization. J. Med. Chem. 2004, 47, 6120–6123. [Google Scholar] [CrossRef]
- Arthuis, M.; Pontikis, R.; Chabot, G.G.; Quentin, L.; Scherman, D.; Florent, J.C. Domino approach to 2-aroyltrimethoxyindoles as novel heterocyclic combretastatin A4 analogues. Eur. J. Med. Chem. 2011, 46, 95–100. [Google Scholar] [CrossRef]
- La Regina, G.; Bai, R.; Rensen, W.; Coluccia, A.; Piscitelli, F.; Gatti, V.; Bolognesi, A.; Lavecchia, A.; Granata, I.; Porta, A.; et al. Design and Synthesis of 2-Heterocyclyl-3-arylthio-1H-indoles as Potent Tubulin Polymerization and Cell Growth Inhibitors with Improved Metabolic Stability. J. Med. Chem. 2011, 54, 8394–8406. [Google Scholar] [CrossRef] [Green Version]
- La Regina, G.; Bai, R.; Rensen, W.M.; DíCesare, E.; Coluccia, A.; Piscitelli, F.; Famiglini, V.; Reggio, A.; Nalli, M.; Pelliccia, S.; et al. Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors. J. Med. Chem. 2013, 56, 123–149. [Google Scholar] [CrossRef]
- La Regina, G.; Edler, M.; Brancale, A.; Kandil, S.; Coluccia, A.; Piscitelli, F.; Hamel, E.; Martino, G.D.; Matesanz, R.; Dı´az, J.F.; et al. New Arythioindoles Inhibitors of Tubulin Polymerization. 3.Biological Evaluation, SAR and Molecular Modeling Studies. J. Med. Chem. 2007, 50, 749–754. [Google Scholar] [CrossRef]
- La Regina, G.; Sarkar, T.; Bai, R.; Edler, M.C.; Saletti, R.; Coluccia, A.; Piscitelli, F.; Minelli, L.; Gatti, V.; Mazzoccoli, C.; et al. New Arylthioindoles and Related Bioisosteres at the Sulfur Bridging Group. 4. Synthesis, Tubulin Polymerization, Cell Growth Inhibition, and Molecular Modeling Studies. J. Med. Chem. 2009, 52, 7512–7527. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tang, S.; Zhou, Z.; Jiang, Z.; Zhu, W.; Qiao, D. Indole-Based Tubulin Inhibitors: Binding Modes and SARs Investigations. Molecules 2022, 27, 1587. [Google Scholar] [CrossRef] [PubMed]
- Baytas, S.N. Recent Advances in Combretastatin A-4 Inspired Inhibitors of Tubulin Polymerization: An Update. Curr. Med. Chem. 2022, 29, 3557–3585. [Google Scholar] [CrossRef] [PubMed]
- De Martino, G.; Edler, M.C.; La Regina, G.; Coluccia, A.; Barbera, M.C.; Barrow, D.; Nicholson, R.I.; Chiosis, G.; Brancale, A.; Hamel, E. New arylthioindoles: Potent Inhibitors of tubulin polymerization. 2. Structure− activity relationships and molecular modeling studies. J. Med. Chem. 2006, 49, 947–954. [Google Scholar] [CrossRef]
- Alvarez, R.; Puebla, P.; Diaz, J.F.; Bento, A.C.; Garcia-Navas, R.; de la Iglesia-Vicente, J.; Mollinedo, F.; Andreu, J.M.; Medarde, M.; Pelaez, R. Endowing indole-based tubulin inhibitors with an anchor for derivatization: Highly potent 3-substituted indolephenstatins and indoleisocombretastatins. J. Med. Chem. 2013, 56, 2813–2827. [Google Scholar] [CrossRef] [Green Version]
- Yan, J.; Chen, J.; Zhang, S.; Hu, J.; Huang, L.; Li, X. Synthesis, evaluation, and mechanism study of novel indole-chalcone derivatives exerting effective antitumor activity through microtubule destabilization in vitro and in vivo. J. Med. Chem. 2016, 59, 5264–5283. [Google Scholar] [CrossRef]
- Ebenezer, O.; Shapi, M.; Tuszynski, J.A. A Review of the Recent Developments of Molecular Hybrids Targeting Tubulin Polymerization. Int. J. Mol. Sci. 2022, 23, 4001. [Google Scholar] [CrossRef]
- Das Mukherjee, D.; Kumar, N.M.; Tantak, M.P.; Das, A.; Ganguli, A.; Datta, S.; Kumar, D.; Chakrabarti, G. Development of Novel Bis(indolyl)-hydrazide-Hydrazone Derivatives as Potent Microtubule-Targeting Cytotoxic Agents against A549 Lung Cancer Cells. Biochemistry 2016, 55, 3020–3035. [Google Scholar] [CrossRef]
- Chen, H.; Deng, S.; Albadari, N.; Yun, M.-K.; Zhang, S.; Li, Y.; Ma, D.; Parke, D.N.; Yang, L.; Seagroves, T.N. Design, Synthesis, and Biological Evaluation of Stable Colchicine-Binding Site Tubulin Inhibitors 6-Aryl-2-benzoyl-pyridines as Potential Anticancer Agents. J. Med. Chem. 2021, 64, 12049–12074. [Google Scholar] [CrossRef]
- Mahboobi, S.; Pongratz, H.; Hufsky, H.; Hockemeyer, J.; Frieser, M.; Lyssenko, A.; Paper, D.H.; Bürgermeister, J.; Böhmer, F.-D.; Fiebig, H.-H. Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents. J. Med. Chem. 2001, 44, 4535–4553. [Google Scholar] [CrossRef]
- Kuo, C.-C.; Hsieh, H.-P.; Pan, W.-Y.; Chen, C.-P.; Liou, J.-P.; Lee, S.-J.; Chang, Y.-L.; Chen, L.-T.; Chen, C.-T.; Chang, J.-Y. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res. 2004, 64, 4621–4628. [Google Scholar] [CrossRef] [Green Version]
- Nien, C.-Y.; Chen, Y.-C.; Kuo, C.-C.; Hsieh, H.-P.; Chang, C.-Y.; Wu, J.-S.; Wu, S.-Y.; Liou, J.-P.; Chang, J.-Y. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. J. Med. Chem. 2010, 53, 2309–2313. [Google Scholar] [CrossRef] [PubMed]
- Sharma, S.; Gupta, M.K.; Saxena, A.K.; Bedi, P.M.S. Triazole linked mono carbonyl curcumin-isatin bifunctional hybrids as novel anti tubulin agents: Design, synthesis, biological evaluation and molecular modeling studies. Bioorganic Med. Chem. 2015, 23, 7165–7180. [Google Scholar] [CrossRef] [PubMed]
- Haider, K.; Shafeeque, M.; Yahya, S.; Yar, M.S. A comprehensive review on pyrazoline based heterocyclic hybrids as potent anticancer agents. Eur. J. Med. Chem. Rep. 2022, 5, 100042. [Google Scholar] [CrossRef]
- Dutta, K.; Majumdar, A.G.; Kushwah, N.; Wadawale, A.P.; Patro, B.S.; Ghosh, S.K. Synthesis of novel indole-oxadiazole molecular hybrids by a regioselective C-3 sulfenylation of indole with 1,3,4-oxadiazole-2-thiols using iodine-dimethyl sulfoxide and their anticancer properties. J. Heterocycl. Chem. 2022, 59, 2165–2176. [Google Scholar] [CrossRef]
- Kamal, A.; Shaik, A.B.; Jain, N.; Kishor, C.; Nagabhushana, A.; Supriya, B.; Bharath Kumar, G.; Chourasiya, S.S.; Suresh, Y.; Mishra, R.K.; et al. Design and synthesis of pyrazole-oxindole conjugates targeting tubulin polymerization as new anticancer agents. Eur. J. Med. Chem. 2015, 92, 501–513. [Google Scholar] [CrossRef]
- Kamal, A.; Reddy, V.S.; Shaik, A.B.; Kumar, G.B.; Vishnuvardhan, M.V.; Polepalli, S.; Jain, N. Synthesis of (Z)-(arylamino)-pyrazolyl/isoxazolyl-2-propenones as tubulin targeting anticancer agents and apoptotic inducers. Org. Biomol. Chem. 2015, 13, 3416–3431. [Google Scholar] [CrossRef]
- Mowery, P.; Filkorn, M.M.; Hurysz, B.; Kwansare, D.O.; Lafferty, M.M.; McFadden, M.A.; Neerukonda, N.D.; Patel, R.R.; Pierce, K.; Sockett, K.A. Discovery of an indole-substituted furanone with tubulin polymerization inhibition activity. Bioorganic Med. Chem. Lett. 2021, 41, 127991. [Google Scholar] [CrossRef]
- Saruengkhanphasit, R.; Butkinaree, C.; Ornnork, N.; Lirdprapamongkol, K.; Niwetmarin, W.; Svasti, J.; Ruchirawat, S.; Eurtivong, C. Identification of new 3-phenyl-1H-indole-2-carbohydrazide derivatives and their structure–activity relationships as potent tubulin inhibitors and anticancer agents: A combined in silico, in vitro and synthetic study. Bioorganic Chem. 2021, 110, 104795. [Google Scholar] [CrossRef]
- Hawash, M.; Kahraman, D.C.; Cetin-Atalay, R.; Baytas, S.N. Induction of Apoptosis in Hepatocellular Carcinoma Cell Lines by Novel Indolylacrylamide Derivatives: Synthesis and Biological Evaluation. Chem. Biodivers. 2021, 18, e2001037. [Google Scholar] [CrossRef]
- Hawash, M.; Kahraman, D.C.; Olgac, A.; Ergun, S.G.; Hamel, E.; Cetin-Atalay, R.; Baytas, S.N. Design and Synthesis of Novel Substituted Indole-acrylamide Derivatives and Evaluation of Their Anti-Cancer Activity as Potential Tubulin-Targeting Agents. J. Mol. Struct. 2022, 1254, 132345. [Google Scholar] [CrossRef]
- Diao, P.-C.; Jian, X.-E.; Chen, P.; Huang, C.; Yin, J.; Huang, J.C.; Li, J.-S.; Zhao, P.-L. Design, synthesis and biological evaluation of novel indole-based oxalamide and aminoacetamide derivatives as tubulin polymerization inhibitors. Bioorganic Med. Chem. Lett. 2020, 30, 126816. [Google Scholar] [CrossRef] [PubMed]
- Romagnoli, R.; Baraldi, P.G.; Lopez-Cara, C.; Preti, D.; Aghazadeh Tabrizi, M.; Balzarini, J.; Bassetto, M.; Brancale, A.; Fu, X.-H.; Gao, Y. Concise synthesis and biological evaluation of 2-aroyl-5-amino benzo [b] thiophene derivatives as a novel class of potent antimitotic agents. J. Med. Chem. 2013, 56, 9296–9309. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hawash, M.M.; Kahraman, D.C.; Eren, F.; Cetin Atalay, R.; Baytas, S.N. Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics. Eur. J. Med. Chem. 2017, 129, 12–26. [Google Scholar] [CrossRef] [PubMed]
- Kuchana, V.; Kashetti, V.; Tangeda, S.J.; Manga, V. Design, synthesis and molecular docking study of thiophenyl hydrazone derivatives as tubulin polymerization inhibitors. Synth. Commun. 2022, 52, 2029–2047. [Google Scholar] [CrossRef]
- Romagnoli, R.; Baraldi, P.G.; Kimatrai Salvador, M.; Preti, D.; Aghazadeh Tabrizi, M.; Bassetto, M.; Brancale, A.; Hamel, E.; Castagliuolo, I.; Bortolozzi, R. Synthesis and biological evaluation of 2-(alkoxycarbonyl)-3-anilinobenzo [b] thiophenes and thieno [2,3-b] pyridines as new potent anticancer agents. J. Med. Chem. 2013, 56, 2606–2618. [Google Scholar] [CrossRef] [Green Version]
- Penthala, N.R.; Madhukuri, L.; Thakkar, S.; Madadi, N.R.; Lamture, G.; Eoff, R.L.; Crooks, P.A. Synthesis and anti-cancer screening of novel heterocyclic-(2H)-1,2,3-triazoles as potential anti-cancer agents. MedChemComm 2015, 6, 1535–1543. [Google Scholar] [CrossRef] [Green Version]
- Kamal, S.; Derbala, H.A.; Alterary, S.S.; Ben Bacha, A.; Alonazi, M.; El-Ashrey, M.K.; Eid El-Sayed, N.N. Synthesis, Biological, and Molecular Docking Studies on 4,5,6,7-Tetrahydrobenzo [b] thiophene Derivatives and Their Nanoparticles Targeting Colorectal Cancer. ACS Omega 2021, 6, 28992–29008. [Google Scholar] [CrossRef]
- Romagnoli, R.; Preti, D.; Hamel, E.; Bortolozzi, R.; Viola, G.; Brancale, A.; Ferla, S.; Morciano, G.; Pinton, P. Concise synthesis and biological evaluation of 2-Aryl-3-Anilinobenzo [b] thiophene derivatives as potent apoptosis-inducing agents. Bioorganic Chem. 2021, 112, 104919. [Google Scholar] [CrossRef]
- Romagnoli, R.; Prencipe, F.; Oliva, P.; Cacciari, B.; Balzarini, J.; Liekens, S.; Hamel, E.; Brancale, A.; Ferla, S.; Manfredini, S. Synthesis and Biological Evaluation of New Antitubulin Agents Containing 2-(3′,4′,5′-trimethoxyanilino)-3,6-disubstituted-4,5,6,7-tetrahydrothieno [2,3-c] pyridine Scaffold. Molecules 2020, 25, 1690. [Google Scholar] [CrossRef]
- Alaylar, B.; Aygün, B.; Turhan, K.; Karadayi, G.; Şakar, E.; Singh, V.; Sayyed, M.; Pelit, E.; Karabulut, A.; Güllüce, M. Characterization of gamma-ray and neutron radiation absorption properties of synthesized quinoline derivatives and their genotoxic potential. Radiat. Phys. Chem. 2021, 184, 109471. [Google Scholar] [CrossRef]
- Wittmann, C.; Bacher, F.; Enyedy, E.A.; Dömötör, O.; Spengler, G.; Madejski, C.; Reynisson, J.; Arion, V.B. Highly Antiproliferative Latonduine and Indolo [2,3-c] quinoline Derivatives: Complex Formation with Copper (II) Markedly Changes the Kinase Inhibitory Profile. J. Med. Chem. 2022, 65, 2238–2261. [Google Scholar] [CrossRef] [PubMed]
- Mathada, B.S. The Versatile Quinoline and Its Derivatives as anti-Cancer Agents: An Overview. Polycycl. Aromat. Compd. 2022, 1–13. [Google Scholar] [CrossRef]
- Lai, M.-J.; Chang, J.-Y.; Lee, H.-Y.; Kuo, C.-C.; Lin, M.-H.; Hsieh, H.-P.; Chang, C.-Y.; Wu, J.-S.; Wu, S.-Y.; Shey, K.-S. Synthesis and biological evaluation of 1-(4′-Indolyl and 6′-Quinolinyl) indoles as a new class of potent anticancer agents. Eur. J. Med. Chem. 2011, 46, 3623–3629. [Google Scholar] [CrossRef] [PubMed]
- Li, W.; Shuai, W.; Sun, H.; Xu, F.; Bi, Y.; Xu, J.; Ma, C.; Yao, H.; Zhu, Z.; Xu, S. Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site. Eur. J. Med. Chem. 2019, 163, 428–442. [Google Scholar] [CrossRef] [PubMed]
- Alswah, M.; Bayoumi, A.H.; Elgamal, K.; Elmorsy, A.; Ihmaid, S.; Ahmed, H.E. Design, synthesis and cytotoxic evaluation of novel chalcone derivatives bearing triazolo [4,3-a]-quinoxaline moieties as potent anticancer agents with dual EGFR kinase and tubulin polymerization inhibitory effects. Molecules 2018, 23, 48. [Google Scholar] [CrossRef] [Green Version]
- Mirzaei, S.; Ghodsi, R.; Hadizadeh, F.; Sahebkar, A. 3D-QSAR-Based Pharmacophore Modeling, Virtual Screening, and Molecular Docking Studies for Identification of Tubulin Inhibitors with Potential Anticancer Activity. BioMed Res. Int. 2021, 2021, 6480804. [Google Scholar] [CrossRef]
- Ren, Y.; Ruan, Y.; Cheng, B.; Li, L.; Liu, J.; Fang, Y.; Chen, J. Design, synthesis and biological evaluation of novel acridine and quinoline derivatives as tubulin polymerization inhibitors with anticancer activities. Bioorganic Med. Chem. 2021, 46, 116376. [Google Scholar] [CrossRef]
- Al-Matarneh, M.C.; Amărandi, R.-M.; Mangalagiu, I.I.; Danac, R. Synthesis and biological screening of new cyano-substituted pyrrole fused (iso) quinoline derivatives. Molecules 2021, 26, 2066. [Google Scholar] [CrossRef]
- Ibrahim, T.S.; Hawwas, M.M.; Malebari, A.M.; Taher, E.S.; Omar, A.M.; Neamatallah, T.; Abdel-Samii, Z.K.; Safo, M.K.; Elshaier, Y.A. Discovery of novel quinoline-based analogues of combretastatin A-4 as tubulin polymerisation inhibitors with apoptosis inducing activity and potent anticancer effect. J. Enzym. Inhib. Med. Chem. 2021, 36, 802–818. [Google Scholar] [CrossRef]
- Hagras, M.; El Deeb, M.A.; Elzahabi, H.S.; Elkaeed, E.B.; Mehany, A.B.; Eissa, I.H. Discovery of new quinolines as potent colchicine binding site inhibitors: Design, synthesis, docking studies, and anti-proliferative evaluation. J. Enzym. Inhib. Med. Chem. 2021, 36, 640–658. [Google Scholar] [CrossRef] [PubMed]
- Ouyang, Y.; Li, J.; Chen, X.; Fu, X.; Sun, S.; Wu, Q. Chalcone Derivatives: Role in Anticancer Therapy. Biomolecules 2021, 11, 894. [Google Scholar] [CrossRef] [PubMed]
- Ngameni, B.; Cedric, K.; Mbaveng, A.T.; Erdoğan, M.; Simo, I.; Kuete, V.; Daştan, A. Design, synthesis, characterization, and anticancer activity of a novel series of O-substituted chalcone derivatives. Bioorganic Med. Chem. Lett. 2021, 35, 127827. [Google Scholar] [CrossRef] [PubMed]
- Liu, W.; He, M.; Li, Y.; Peng, Z.; Wang, G. A review on synthetic chalcone derivatives as tubulin polymerisation inhibitors. J. Enzym. Inhib. Med. Chem. 2022, 37, 9–38. [Google Scholar] [CrossRef]
- Sharma, S.; Kaur, C.; Budhiraja, A.; Nepali, K.; Gupta, M.K.; Saxena, A.; Bedi, P. Chalcone based azacarboline analogues as novel antitubulin agents: Design, synthesis, biological evaluation and molecular modelling studies. Eur. J. Med. Chem. 2014, 85, 648–660. [Google Scholar] [CrossRef]
- Oskuei, S.R.; Mirzaei, S.; Jafari-Nik, M.R.; Hadizadeh, F.; Eisvand, F.; Mosaffa, F.; Ghodsi, R. Design, synthesis and biological evaluation of novel imidazole-chalcone derivatives as potential anticancer agents and tubulin polymerization inhibitors. Bioorganic Chem. 2021, 112, 104904. [Google Scholar] [CrossRef]
- Wang, G.; Liu, W.; Gong, Z.; Huang, Y.; Li, Y.; Peng, Z. Design, synthesis, biological evaluation and molecular docking studies of new chalcone derivatives containing diaryl ether moiety as potential anticancer agents and tubulin polymerization inhibitors. Bioorganic Chem. 2020, 95, 103565. [Google Scholar] [CrossRef]
- Wang, G.; Liu, W.; Gong, Z.; Huang, Y.; Li, Y.; Peng, Z. Synthesis, biological evaluation, and molecular modelling of new naphthalene-chalcone derivatives as potential anticancer agents on MCF-7 breast cancer cells by targeting tubulin colchicine binding site. J. Enzym. Inhib. Med. Chem. 2020, 35, 139–144. [Google Scholar] [CrossRef]
- Wang, G.; Liu, W.; Fan, M.; He, M.; Li, Y.; Peng, Z. Design, synthesis and biological evaluation of novel thiazole-naphthalene derivatives as potential anticancer agents and tubulin polymerisation inhibitors. J. Enzym. Inhib. Med. Chem. 2021, 36, 1694–1702. [Google Scholar] [CrossRef]
- Sun, Y.-X.; Song, J.; Kong, L.-J.; Sha, B.-B.; Tian, X.-Y.; Liu, X.-J.; Hu, T.; Chen, P.; Zhang, S.-Y. Design, synthesis and evaluation of novel bis-substituted aromatic amide dithiocarbamate derivatives as colchicine site tubulin polymerization inhibitors with potent anticancer activities. Eur. J. Med. Chem. 2022, 229, 114069. [Google Scholar] [CrossRef]
- Song, J.; Wang, S.-H.; Song, C.-H.; Zhang, W.-X.; Zhu, J.-X.; Tian, X.-Y.; Fu, X.-J.; Xu, Y.; Jin, C.-Y.; Zhang, S.-Y. Discovery of N-benzylarylamide derivatives as novel tubulin polymerization inhibitors capable of activating the Hippo pathway. Eur. J. Med. Chem. 2022, 240, 114583. [Google Scholar] [CrossRef] [PubMed]
- Mohamed, H.S.; Amin, N.H.; El-Saadi, M.T.; Abdel-Rahman, H.M. Design, synthesis, biological assessment, and in-silico studies of 1,2,4-triazolo [1,5-a] pyrimidine derivatives as tubulin polymerization inhibitors. Bioorganic Chem. 2022, 121, 105687. [Google Scholar] [CrossRef] [PubMed]
- Pal, S.; Azad, A.; Bhatia, S.; Drabkin, H.; Costello, B.; Sarantopoulos, J.; Kanesvaran, R.; Lauer, R.; Starodub, A.; Hauke, R. A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma. Clin. Cancer Res. 2015, 21, 3420–3427. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hawash, M.; Kahraman, D.C.; Ergun, S.G.; Cetin-Atalay, R.; Baytas, S.N. Synthesis of novel indole-isoxazole hybrids and evaluation of their cytotoxic activities on hepatocellular carcinoma cell lines. BMC Chem. 2021, 15, 66. [Google Scholar] [CrossRef] [PubMed]
- Hao, S.-Y.; Qi, Z.-Y.; Wang, S.; Wang, X.-R.; Chen, S.-W. Synthesis and bioevaluation of N-(3,4,5-trimethoxyphenyl)-1H-pyrazolo [3,4-b] pyridin-3-amines as tubulin polymerization inhibitors with anti-angiogenic effects. Bioorganic Med. Chem. 2021, 31, 115985. [Google Scholar] [CrossRef] [PubMed]
- Liu, R.; Huang, M.; Zhang, S.; Li, L.; Li, M.; Sun, J.; Wu, L.; Guan, Q.; Zhang, W. Design, synthesis and bioevaluation of 6-aryl-1-(3,4,5-trimethoxyphenyl)-1H-benzo [d] imidazoles as tubulin polymerization inhibitors. Eur. J. Med. Chem. 2021, 226, 113826. [Google Scholar] [CrossRef]
- Huo, X.-S.; Jian, X.-E.; Ou-Yang, J.; Chen, L.; Yang, F.; Lv, D.-X.; You, W.-W.; Rao, J.-J.; Zhao, P.-L. Discovery of highly potent tubulin polymerization inhibitors: Design, synthesis, and structure-activity relationships of novel 2,7-diaryl-[1,2,4] triazolo [1,5-a] pyrimidines. Eur. J. Med. Chem. 2021, 220, 113449. [Google Scholar] [CrossRef]
- Wang, B.; Wang, L.-R.; Liu, L.-L.; Wang, W.; Man, R.-J.; Zheng, D.-J.; Deng, Y.-S.; Yang, Y.-S.; Xu, C.; Zhu, H.-L. A novel series of benzothiazepine derivatives as tubulin polymerization inhibitors with anti-tumor potency. Bioorganic Chem. 2021, 108, 104585. [Google Scholar] [CrossRef]
- Ansari, M.; Shokrzadeh, M.; Karima, S.; Rajaei, S.; Fallah, M.; Ghassemi-Barghi, N.; Ghasemian, M.; Emami, S. New thiazole-2 (3H)-thiones containing 4-(3,4,5-trimethoxyphenyl) moiety as anticancer agents. Eur. J. Med. Chem. 2020, 185, 111784. [Google Scholar] [CrossRef]
- Škubník, J.; Pavlíčková, V.S.; Ruml, T.; Rimpelová, S. Vincristine in Combination Therapy of Cancer: Emerging Trends in Clinics. Biology 2021, 10, 849. [Google Scholar] [CrossRef]
- Wu, Q.; Qian, W.; Sun, X.; Jiang, S. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J. Hematol. Oncol. 2022, 15, 143. [Google Scholar] [CrossRef] [PubMed]
- Alqahtani, F.Y.; Aleanizy, F.S.; El Tahir, E.; Alkahtani, H.M.; AlQuadeib, B.T. Paclitaxel. In Profiles of Drug Substances, Excipients and Related Methodology; Elsevier: Amsterdam, The Netherlands, 2019; Volume 44, pp. 205–238. [Google Scholar]
- Cortazar, P.; Justice, R.; Johnson, J.; Sridhara, R.; Keegan, P.; Pazdur, R. US Food and Drug Administration approval overview in metastatic breast cancer. J. Clin. Oncol. 2012, 30, 1705. [Google Scholar] [CrossRef] [PubMed]
- van Vuuren, R.J.; Visagie, M.H.; Theron, A.E.; Joubert, A.M. Antimitotic drugs in the treatment of cancer. Cancer Chemother. Pharmacol. 2015, 76, 1101–1112. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Burns, C.J.; Wilks, A.F.; Harte, M.F.; Sikanyika, H.; Fantino, E. Substituted Pyrazines as Tubulin Inhibitors. U.S. Patent No. 9,139,560, 22 September 2015. [Google Scholar]
- Kamal, A.; Prasad, B.; Nayak, V.L.; Reddy, V.S.; Reddy, N.V.S. N-((1-Benzyl-1H-1,2,3-triazol-4-yl)methyl) Arylamide Compounds as Potential Anticancer Agents and a Process for the Preparation Thereof. U.S. Patent No. 9309225, 12 April 2016. [Google Scholar]
- Thorn-Seshold, O.; Borowiak, M.; Trauner, D.; Hasserodt, J. Azoaryls as reversibly modulatable tubulin inhibitors. Google Patents 2017. [Google Scholar]
- Cao, X.; Li, B.; Chen, J.; Dang, J.; Chen, S.; Gunes, E.G.; Xu, B.; Tian, L.; Muend, S.; Raoof, M. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer. J. Immunother. Cancer 2021, 9, e002022. [Google Scholar] [CrossRef] [PubMed]
- Tong, J.T.; Harris, P.W.; Brimble, M.A.; Kavianinia, I. An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. Molecules 2021, 26, 5847. [Google Scholar] [CrossRef] [PubMed]
Drug Name | Chemical Structure | Type of Cancer | Microtubule | Status |
---|---|---|---|---|
Paclitaxel [135] | Metastatic adenocarcinoma of the pancreas | Stabilizing | Approved in 1998 | |
Ixabepilone [136] | Metastatic or locally advanced breast cancer | Microtubule-stabilizing | Approved in 2007 | |
Eribulin [137] | Recurrent metastatic breast cancer | Microtubule-destabilizing | Approved in 2010 | |
BNC105P [19] | Leukemia | Inhibit polymerization | Phase I clinical trials | |
Plinabulin [138] | Lung Cancer | Inhibit polymerization | Phase I clinical trials | |
Tesetaxel [139] | Breast Cancer | Stabilizing | Phase III clinical trials | |
KX2-361 [140] | Solid Tumor | Inhibits polymerization | Phase I clinical trials | |
Fosbretabulin [18] | Thyroid cancer | Microtubule-destabilizing | Approved in 2018 | |
Cabazitaxel [141] | Metastatic, hormone-resistant prostate cancer | Stabilizing | Approved in 2019 | |
Monomethyl Auristatin E [142] | Metastatic cervical cancer | Microtubule-disrupting agent (in conjugation with antibody) | Approved in 2021 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hawash, M. Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy. Biomolecules 2022, 12, 1843. https://doi.org/10.3390/biom12121843
Hawash M. Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy. Biomolecules. 2022; 12(12):1843. https://doi.org/10.3390/biom12121843
Chicago/Turabian StyleHawash, Mohammed. 2022. "Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy" Biomolecules 12, no. 12: 1843. https://doi.org/10.3390/biom12121843